PN-943: complete guide

PN-943 is an investigational gut-restricted peptide that blocks alpha4beta7 integrin. This guide covers its design, mechanism, ulcerative colitis trials, safety and status.

Complete guide5 min read

Key takeaway

PN-943 completed a Phase 2 ulcerative colitis trial with 169 participants in February 2023. Protagonist reported that one of its two PN-943 groups missed the prespecified primary endpoint. In its 2023 annual report, the company said it does not intend to dedicate further internal resources to the program.

At a glance

Article typeComplete guide
Regulatory statusNot FDA-approved“PN-943 is not approved by the FDA for any use.” (this article)
ClassGut & digestion
Body systemsGut
Studies cited2 in this article · 2 across 1 article on PN-943
Related productsResearch peptide catalog

PN-943 is an experimental gut-restricted peptide from Protagonist Therapeutics that blocks the α4β7 integrin, a protein that steers immune cells into the gut. It was tested in ulcerative colitis. This guide covers its design, mechanism, trials, safety data and current status. Sources were checked on November 17, 2026.

Quick answer: PN-943 is a second-generation α4β7 integrin antagonist peptide designed to act inside the gut with low exposure elsewhere. It followed Protagonist’s earlier peptide PTG-100. No peer-reviewed efficacy results have been published. It is not FDA-approved, and its developer has stopped internal investment in it.

Vitrapep does not sell PN-943; this page is a reference summary of published research and regulatory information.

What is PN-943?

PN-943 is a synthetic peptide. A 2021 study describes it as a “gastrointestinal-restricted peptide” that binds α4β7 integrin on white blood cells (Modi et al., 2021). “Gastrointestinal-restricted” means it is designed to stay in the gut, with little reaching the bloodstream.

Protagonist’s 2021 annual report describes it as “a second-generation” α4β7-specific integrin antagonist. The filing says PN-943 “may be a more potent α4β7 integrin antagonist compound than PTG-100,” the company’s first-generation peptide (Protagonist 10-K, 2022). Our primer on what peptides are covers the basics.

We found no PubChem record for PN-943, and its chemical formula and molecular weight were not published in the sources we checked. Protagonist also sponsored the trials of another peptide, rusfertide.

Table 1

PN-943: key facts

Fact Detail
Structure type Synthetic peptide, designed to be gut-restricted
Class α4β7 integrin antagonist (second generation, after PTG-100)
Molecular formula Not disclosed in the sources we checked
Molecular weight Not disclosed in the sources we checked
Development stage Phase 2 in ulcerative colitis completed (2023); no further internal development planned (2024 filing)
Sponsor or developer Protagonist Therapeutics, Inc.

How does PN-943 work?

White blood cells enter the gut lining by docking onto blood vessel walls. One docking pair is the α4β7 integrin on the immune cell and MAdCAM-1 on the vessel. The NCBI gene record says MAdCAM-1 “interacts preferentially with the leukocyte beta7 integrin LPAM-1 (alpha4beta7).” Its role is “to direct leukocytes into mucosal and inflamed tissues” (NCBI Gene, MADCAM1).

Protagonist states that “by blocking the binding of α4β7 integrin to MAdCAM-1, PN-943 may prevent trafficking and activation of T cells.” The approved antibody vedolizumab (Entyvio) works on the same target. Its label says it “specifically binds to the α4β7 integrin” (Entyvio label, 2026). Entyvio is an antibody, while PN-943 is a much smaller peptide. Our explainer on how peptides work covers receptor blockers.

What is PN-943 being studied for?

PN-943 is not approved by the FDA for any use. ClinicalTrials.gov lists one patient trial:

  • moderate to severe active ulcerative colitis, Phase 2, IDEAL, randomized and triple-masked, 169 enrolled (NCT04504383, completed February 2023, no results posted).

Its predecessor PTG-100 had its own Phase 2 ulcerative colitis trial. That trial ended early. The registry reason reads: “Data Monitoring Committee discontinued the trial due to futility-based outcome” (NCT02895100). Other gut-focused peptides in our library include larazotide acetate and linaclotide.

What did the key trials show?

Phase 1 in healthy volunteers. These human studies enrolled 40 men in a single-exposure study and 57 in a repeat-exposure study. A third crossover study enrolled 10 people. Systemic exposure was low, consistent with the gut-restricted design. The authors reported rising receptor occupancy in blood, “supporting target engagement” on circulating cells (Modi et al., 2021).

Phase 2 IDEAL in ulcerative colitis. This randomized, placebo-controlled human trial compared two PN-943 groups with placebo. In April 2022, Protagonist reported that one PN-943 group “did not meet the prespecified primary endpoint” (Protagonist, 2022). No results are posted on ClinicalTrials.gov. We found no peer-reviewed report of the trial, so we do not summarize its efficacy here.

PTG-100 background. The predecessor’s Phase 2a study “initially did not meet the primary endpoint.” A blinded reread of endoscopy videos by a third party later indicated clinical efficacy, the authors reported (Sandborn et al., 2021).

What side effects have studies reported?

In the Phase 1 studies, PN-943 was “generally well tolerated.” The authors stated that “no subjects discontinued due to treatment-emergent adverse events” (Modi et al., 2021). These were healthy men, not patients with colitis.

Adverse event data from the IDEAL trial in ulcerative colitis have not been posted on ClinicalTrials.gov. We found no peer-reviewed safety report from it.

What is PN-943’s regulatory status, and how is it used in research?

PN-943 is an investigational compound. Protagonist filed its annual report for 2023 in 2024. It states: “We completed a Phase 2 trial of PN-943 in patients with moderate to severe UC in early 2023.” It also says the company does not intend “to dedicate further internal resources” to clinical development or manufacturing for the program (Protagonist 10-K, 2024).

The filing still calls PN-943 “wholly owned.” We found no FDA designation or warning for PN-943 in the sources we checked. Its published human data come from Phase 1 pharmacology work, which measured drug levels and receptor occupancy rather than disease outcomes.

Frequently asked questions about PN-943

Is PN-943 a peptide?

Yes. Its developers describe it as a gastrointestinal-restricted peptide antagonist of α4β7 integrin.

Is PN-943 FDA-approved?

No. It completed one Phase 2 trial, and its developer has stopped internal investment in it.

How is PN-943 related to PTG-100?

PTG-100 was Protagonist’s first-generation α4β7 antagonist peptide. PN-943 was its second-generation successor.

How does PN-943 compare with vedolizumab?

Both target α4β7 integrin. Vedolizumab is an FDA-approved antibody; PN-943 is an unapproved peptide designed to stay in the gut.

Were the IDEAL trial results published?

Not in a peer-reviewed journal that we could find, and no results are posted on ClinicalTrials.gov.

What to know now

  • Design: gut-restricted synthetic peptide; second-generation α4β7 integrin antagonist.
  • Mechanism: blocks α4β7 binding to MAdCAM-1, which guides immune cells into the gut.
  • Evidence: Phase 1 showed target engagement; Phase 2 IDEAL efficacy unpublished.
  • Safety: generally well tolerated in healthy volunteers.
  • Status: not FDA-approved; no further internal development by Protagonist.

What we’re watching

Any posting of IDEAL results on ClinicalTrials.gov (NCT04504383) or a peer-reviewed paper. Any partnering or licensing of PN-943 disclosed in Protagonist filings. Related guides: larazotide acetate and rusfertide.

More for gut

All 11 compounds for gut

Sources: Modi 2021, Clinical Pharmacology in Drug Development, 10; Sandborn 2021, Gastroenterology, 161; Protagonist Therapeutics 2020, PN-943 in adults with moderate to severe active ulcerative colitis (UC); Protagonist Therapeutics 2016; Protagonist Therapeutics 2022; Protagonist Therapeutics 2022, Form 10-K for the fiscal year ended December 31, 2021; Protagonist Therapeutics 2024, Form 10-K for the fiscal year ended December 31, 2023; National Center for Biotechnology Information 2026, Gene ID 8174, MADCAM1 mucosal vascular addressin cell adhesion molecule 1 (Homo sapiens); Takeda Pharmaceuticals America 2026, ENTYVIO (vedolizumab) prescribing information. All 9 citations

Back to the research library

References

  1. Modi, N. B., et al. (2021). Single- and multiple-dose pharmacokinetics and pharmacodynamics of PN-943, a gastrointestinal-restricted oral peptide antagonist of α4β7, in healthy volunteers. Clinical Pharmacology in Drug Development, 10(11), 1263-1278. https://doi.org/10.1002/cpdd.946
  2. Sandborn, W. J., et al. (2021). PTG-100, an oral α4β7 antagonist peptide: Preclinical development and phase 1 and 2a studies in ulcerative colitis. Gastroenterology, 161(6), 1853-1864.e10. https://doi.org/10.1053/j.gastro.2021.08.045
  3. Protagonist Therapeutics, Inc. (2020). PN-943 in adults with moderate to severe active ulcerative colitis (UC) (ClinicalTrials.gov ID NCT04504383). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04504383
  4. Protagonist Therapeutics, Inc. (2016). Safety and efficacy study of PTG-100 in the treatment of moderate to severe ulcerative colitis (ClinicalTrials.gov ID NCT02895100). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT02895100
  5. Protagonist Therapeutics, Inc. (2022, April 25). Protagonist Therapeutics announces topline data from Phase 2 IDEAL study of PN-943 in ulcerative colitis [Press release]. BioSpace. https://www.biospace.com/protagonist-therapeutics-announces-topline-data-from-phase-2-ideal-study-of-pn-943-in-ulcerative-colitis
  6. Protagonist Therapeutics, Inc. (2022). Form 10-K for the fiscal year ended December 31, 2021. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1377121/000155837022002385/ptgx-20211231x10k.htm
  7. Protagonist Therapeutics, Inc. (2024). Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1377121/000155837024001850/ptgx-20231231x10k.htm
  8. National Center for Biotechnology Information. (2026). Gene ID 8174, MADCAM1 mucosal vascular addressin cell adhesion molecule 1 (Homo sapiens). Retrieved November 17, 2026, from https://www.ncbi.nlm.nih.gov/gene/8174
  9. Takeda Pharmaceuticals America, Inc. (2026). ENTYVIO (vedolizumab) prescribing information (revised 2/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c